Shanghai Junshi Biosciences Co., Ltd announced FDA approval for a phase 2/3 clinical study comparing their product, JS207, to nivolumab for neoadjuvant treatment of NSCLC. Lung cancer has high prevalence and mortality rates worldwide. JS207 is the first PD-1/VEGF dual-target drug approved for this study. JS207 has shown promise in POC studies targeting prevalent cancers globally. The drug aims to offer better treatments and a brighter future for patients. JS207’s design is based on the high-affinity, clinically proven anti-PD-1 drug, toripalimab, and shows enhanced efficacy in vitro tests. Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to developing innovative therapeutics.

Read more at GlobeNewswire: Junshi Biosciences Announces FDA’s Approval of IND